Targovax ASA: Second quarter and first half year 2022 results
Oslo, Norway, 18 August 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its second quarter and first half year 2022 results. Members of Targovax’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).FIRST HALF YEAR 2022 HIGHLIGHTS ONCOS-102 · Signed a clinical collaboration agreement with Agenus for PD-1 and CTLA-4 checkpoint inhibitor supply to the upcoming ONCOS-102 phase 2 melanoma trial